ArticleKidney & blood pressure research2026
SIRT6 Attenuates Angiotensin II-Induced Podocyte Cholesterol Accumulation and Injury via Negative Modulation of SREBP2.
Article in Kidney & blood pressure research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAngiotensin (Ang) II can cause podocyte injury and leads to chronic kidney disease (CKD), but the specific mechanism is not clear. In our previous study, we found that Ang II reduced the expression of cholesterol efflux-associated molecule by regulating sirtuin 6 (SIRT6), thereby inducing podocyte cholesterol accumulation and injury. However, the effect of SIRT6 on podocyte cholesterol synthesis is unclear. In this study, we evaluated the role of SIRT6 in the expression of cholesterol synthesis-associated molecular sterol regulatory element-binding protein 2 (SREBP2), cholesterol content, and apoptosis levels in podocytes.
methodsAng II-infused rat model was constructed. Cholesterol quantification was examined using a cholesterol quantitation kit. The expression of SIRT6 and SREBP2 was examined by Western blot and immunofluorescence assay. The podocyte apoptotic level was detected by flow cytometry. Transfection of podocytes with pcDNA3.1 SIRT6 plasmid and the deacetylase-inactive SIRT6 mutant plasmid (pcDNA3.1 SIRT6 H133Y) was performed to investigate whether SIRT6 regulates SREBP2 expression and to further determine if this regulatory effect is dependent on SIRT6's deacetylase activity.
resultsAng II promoted lipid droplet and cholesterol accumulation in rat glomeruli, suppressed SIRT6 expression, and enhanced SREBP2 activation, evidenced by increased SREBP2 levels and nuclear translocation. Transfection of pcDNA3.1 SIRT6 into podocytes attenuated SREBP2 activation, reducing Ang II-induced cholesterol accumulation and apoptosis. Experiments using pcDNA3.1 SIRT6 and pcDNA3.1 SIRT6 H133Y plasmids indicate that SIRT6-mediated suppression of SREBP2 requires its histone deacetylase activity.
conclusionWe conclude that SIRT6 serves as a key protective regulator of podocytes against RAS activation, at least in part by suppressing SREBP2 expression and thereby alleviating cholesterol accumulation and associated podocyte injury. It provides a new target for clinical treatment of CKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.